<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03021018</url>
  </required_header>
  <id_info>
    <org_study_id>EP0087</org_study_id>
    <nct_id>NCT03021018</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting</brief_title>
  <official_title>A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV)
      compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy
      Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">April 27, 2018</completion_date>
  <primary_completion_date type="Actual">April 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to next seizure (per clinical observation with electroencephalogram [EEG] confirmation) or rescue medication</measure>
    <time_frame>During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)</time_frame>
    <description>This variable is calculated in hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to next seizure (per clinical observation) or rescue medication</measure>
    <time_frame>During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)</time_frame>
    <description>This variable is calculated in hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are seizure-free per clinical observation at 6 hours after the end of study drug administration</measure>
    <time_frame>At 6 hours after the end of study drug administration</time_frame>
    <description>This variable is defined as the number of subjects seizure free during 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat (ITT) set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are seizure-free per clinical observation at 8 hours after the end of study drug administration</measure>
    <time_frame>At 8 hours after the end of study drug administration</time_frame>
    <description>This variable is defined as the number of subjects seizure free during 8 hours after the end of study drug administration divided by the number of subjects in the ITT set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are seizure-free per clinical observation at 12 hours after the end of study drug administration</measure>
    <time_frame>At 12 hours after the end of study drug administration</time_frame>
    <description>This variable is defined as the number of subjects seizure free during 12 hours after the end of study drug administration divided by the number of subjects in the ITT set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who receive rescue medication during the 6 hours after the end of study drug administration</measure>
    <time_frame>During the 6 hours after the end of study drug administration</time_frame>
    <description>This variable is defined as the number of subjects who received rescue medication with start date and time within the first 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat as randomized (ITT-R) set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who receive rescue medication during the 8 hours after the end of study drug administration</measure>
    <time_frame>During the 8 hours after the end of study drug administration</time_frame>
    <description>This variable is defined as the number of subjects who received rescue medication with start date and time within the first 8 hours after the end of study drug administration divided by the number of subjects in the ITT-R set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who receive rescue medication during the 12 hours after the end of study drug administration</measure>
    <time_frame>During the 12 hours after the end of study drug administration</time_frame>
    <description>This variable is defined as the number of subjects who received rescue medication with start date and time within the first 12 hours after the end of study drug administration divided by the number of subjects in the ITT-R set.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Brivaracetam (BRV) 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam (BRV) 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorazepam (LZP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Pharmaceutical Form: Solution for infusion
Concentration: 10 mg/ml
Route of Administration: intravenous</description>
    <arm_group_label>Brivaracetam (BRV) 100 mg</arm_group_label>
    <arm_group_label>Brivaracetam (BRV) 200 mg</arm_group_label>
    <other_name>Briviact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>Pharmaceutical Form: Solution for injection
Route of Administration: intravenous</description>
    <arm_group_label>Lorazepam (LZP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female, 18 to 70 years of age, inclusive

          -  Subject has an established diagnosis of epilepsy

          -  Subject has been admitted to the institution's Epilepsy Monitoring Unit (EMU) for
             seizure characterization or noninvasive presurgical evaluation or such admission is
             planned within 21 days of Screening

        Exclusion Criteria:

          -  Subject has previously participated in this study and was treated with study drug.
             Re-screen is permitted

          -  Subject has participated in another study of an investigational medicinal product
             (IMP) or a medical device within the previous 30 days of Epilepsy Monitoring Unit
             (EMU) admission or is currently participating in another study of an IMP or a medical
             device

          -  Subject has taken brivaracetam (BRV) or Levetiracetam (LEV) in the 21 days prior to
             EMU admission

          -  History or presence of status epilepticus during the 6 months prior to EMU admission

          -  Subject has a medical or psychiatric condition that in the opinion of the Investigator
             could jeopardize or would compromise the subject's ability to participate in this
             study

          -  Subject has &gt; 2x upper limit of normal (ULN) of any of the following: alanine
             aminotransferase, aspartate aminotransferase, alkaline phosphatase, or &gt; ULN total
             bilirubin

          -  Subject has chronic liver disease

          -  Subject has hypersensitivity to BRV or any of its excipients

          -  Subject has a history of alcohol or drug abuse during the 6 months prior to EMU
             admission

          -  Subject with a history of psychogenic seizures

          -  Subject is a pregnant or lactating female

          -  Subject has a history of a significant Adverse Event (AE) due to a benzodiazepine in
             the opinion of the Investigator

          -  Subject has respiratory failure (or is at risk for respiratory failure), untreated
             sleep apnea, or other severe cardiorespiratory disease with New York Heart Association
             Class III or IV functional status, or requires supplemental oxygen

          -  Subject has acute narrow-angle glaucoma or myasthenia gravis

          -  Subject is receiving benzodiazepine treatment (defined as an average of &gt;=4
             administrations per week) that started less than 28 days prior to EMU admission

          -  Subject has a known allergic reaction or intolerance to benzodiazepines or
             benzodiazepine excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>UCB (+1 844 599 2273)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ep0087 108</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 104</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 117</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 110</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 112</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 115</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 113</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 119</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 116</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 106</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 107</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 125</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 120</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 121</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 105</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0087 123</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-2360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Brivaracetam</keyword>
  <keyword>Epilepsy Monitoring Unit</keyword>
  <keyword>Increased seizure activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

